Neuroblastoma – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of neuroblastoma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations in these markets, we estimate the number of drug-treatment opportunities in specific lines of therapy.

Clarivate Epidemiology’s neuroblastoma forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with neuroblastoma each year?
  • How will improvements in survival change the number of people living with a diagnosis of neuroblastoma?
  • How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for neuroblastoma?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of neuroblastoma over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

Clarivate Epidemiology forecasts the following neuroblastoma patient populations:

  • Diagnosed incident cases.
  • Diagnosed incident cases of localized disease.
  • Diagnosed incident cases of regional disease.
  • Diagnosed incident cases of distant disease.
  • Diagnosed incident cases of metastatic recurrent disease.
  • Diagnosed prevalent cases.
  • Diagnosed first-line drug-treatable population.

Note: Coverage may vary by country.

launch Related Market Assessment Reports